Home 2017-01-21T19:49:53+00:00

IN THE NEWS
2303, 2017

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results Five Phase 2 Programs in Four Orphan IndicationsMultiple Value-Creating Events Across Programs Expected in Next 12-18 MonthsPALO ALTO, Calif., March 23, 2017 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today a business update and financial results for the three months and full year ended December 31, 2016.“We believe that 2016, Eiger’s first year as a publicly traded company, was a year of significant accomplishment and advancement,” said David Cory, President and CEO of Eiger BioPharmaceuticals.  “We advanced our [...]

3101, 2017

Eiger BioPharmaceuticals to Present at BIO CEO & Investor Conference February 13th and Participate in SunTrust Robinson Humphrey Orphan Drug Day Conference February 14th

Eiger BioPharmaceuticals to Present at BIO CEO & Investor Conference February 13th and Participate in SunTrust Robinson Humphrey Orphan Drug Day Conference February 14th PALO ALTO, Calif. – January 30, 2017 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory, President and CEO of Eiger, will present a corporate overview and business update at the 19th Annual BIO CEO & Investor Conference at 10:00 am ET on Monday, February 13, 2017, at the Waldorf Astoria Hotel in New York City. A live webcast of the presentation [...]

401, 2017

Eiger Completes $25 Million Debt Financing with Oxford Finance

Eiger Completes $25 Million Debt Financing with Oxford Finance PALO ALTO, Calif., January 4, 2017 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, today announced that it has completed a $25 million debt financing transaction with Oxford Finance LLC (“Oxford”), a specialty finance firm that provides senior debt to life sciences and healthcare services companies worldwide.  Proceeds of the financing are intended for use to advance Eiger’s diverse pipeline of clinical stage programs for the treatment of rare diseases, including the Company’s lead program for hepatitis delta virus (HDV) infection, the [...]